Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor

Theranostics

Volumn 7, Issue 2, 2017, Pages 308-318

  Hultqvist, Greta ^a   Syvänen, Stina ^a   Fang, Xiaotian T ^a   Lannfelt, Lars ^a   Sehlin, Dag ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Antibodies; BBB shuttle; Immunotherapy; PET; TfR

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 158; RECEPTOR ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; BLOOD BRAIN BARRIER; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ELIMINATION; DRUG HALF LIFE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HIPPOCAMPUS; ISOTOPE LABELING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TRANSPORT; RADIOACTIVITY; RADIOCHEMISTRY; THALAMUS; ANIMAL; BRAIN CHEMISTRY; DISEASE MODEL; GENETICS; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; RECEPTORS, TRANSFERRIN; RECOMBINANT PROTEINS;

EID: 85008462862     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.17155     Document Type: Article

References (29)

1. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6:916-919.
2. Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 2009; 102:1251-1258.
3. Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv 2015; 12:207-222.
4. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Sci Transl Med 2011; 3:84ra44-84ra44.
5. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron 2014; 81:49-60.
6. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta Oligomerization in Alzheimer Dementia vs. High Pathology Controls. Ann Neurol 2013; 73:104-119.
7. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Konrad Vbeyreuther, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46:860-866.
8. Näslund J, Haroutunian V, Mohs R, et al. COrrelation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283:1571-1577.
9. Fowler SW, Chiang ACA, Savjani RR, Larson ME, Sherman MA, Schuler DR, et al. Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease. J Neurosci 2014; 34:7871-7885.
10. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, et al. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 2010; 24:2716-2726.
11. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization. J Neurosci 2008; 28:4231-4237.
12. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001; 4:887-893.
13. Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation. PLoS ONE 2012; 7:e32014.
14. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-842.
15. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
16. Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem 2007; 103:334-345.
17. Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, et al. Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain. J Alzheimers Dis 2013; 37:29-40.
18. Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S, et al. Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies. Neurodegener Dis 2011; 8:117-123.
19. Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer/'s disease. Nat Commun 2016; 7:10759.
20. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32:1959-1972.
21. Zuchero YJY, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, et al. Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies. Neuron 2016; 89:70-82.
22. Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Söderberg L, et al. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2009; 36:425-434.
23. Todd MM, Weeks JB, Warner DS. Microwave fixation for the determination of cerebral blood volume in rats. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 1993; 13:328-336.
24. Boado RJ, Zhou Q-H, Lu JZ, Hui EK-W, Pardridge WM. Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin Receptor. Mol Pharm 2010; 7:237-244.
25. Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001; 14:1025-1033.
26. Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DL, Wurm FM. Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol Bioeng 2008; 101:182-189.
27. Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89:114-123.
28. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003; 2:131-137.
29. Ma Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Slatest L, et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 2005; 135:1203-1215.